肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

2019年癌症免疫疗法学会（SITC）年会：研究性黑素瘤疫苗Seviprotimut-L的III期中期数据

2019-11-07 Allan MedSci原创

黑素瘤疫苗SITCSeviprotimut
关注

Polynoma LLC是一家专注于免疫肿瘤学的生物制药公司。Polynoma LLC将于11月8日在马里兰州举行的2019年癌症免疫治疗学会（SITC）年会上展示黑色素瘤疫苗候选药物seviprotimut-L的III期临床研究（MAVIS研究）。

Polynoma LLC是一家专注于免疫肿瘤学的生物制药公司。Polynoma LLC将于11月8日在马里兰州举行的2019年癌症免疫治疗学会（SITC）年会上展示黑色素瘤疫苗候选药物seviprotimut-L的III期临床研究（MAVIS研究）。

MAVIS是一项多中心、双盲、安慰剂对照的适应性III期试验，旨在评估seviprotimut-L的安全性和有效性，其主要终点是手术切除后高复发风险的IIA / C，IIIA，IIIB / C期黑色素瘤患者的无复发生存期（RFS）和总体生存期（OS）。


原始出处：

http://www.firstwordpharma.com/node/1679058#axzz64Xy4dOaT

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916186, encodeId=89fa191618662, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 12 02:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910527, encodeId=5a23191052eb0, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Wed Sep 23 12:45:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746689, encodeId=7a7d1e46689ea, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Mon Mar 16 04:45:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479430, encodeId=395514e9430ee, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594667, encodeId=ebd1159466ec7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602209, encodeId=a77316022090a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
    2020-02-12 juliusluan78

    #III#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1916186, encodeId=89fa191618662, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 12 02:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910527, encodeId=5a23191052eb0, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Wed Sep 23 12:45:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746689, encodeId=7a7d1e46689ea, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Mon Mar 16 04:45:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479430, encodeId=395514e9430ee, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594667, encodeId=ebd1159466ec7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602209, encodeId=a77316022090a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
    2020-09-23 zhanglin3079

    #SIT#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1916186, encodeId=89fa191618662, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 12 02:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910527, encodeId=5a23191052eb0, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Wed Sep 23 12:45:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746689, encodeId=7a7d1e46689ea, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Mon Mar 16 04:45:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479430, encodeId=395514e9430ee, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594667, encodeId=ebd1159466ec7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602209, encodeId=a77316022090a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
    2020-03-16 chendoc254

    #VIP#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1916186, encodeId=89fa191618662, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 12 02:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910527, encodeId=5a23191052eb0, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Wed Sep 23 12:45:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746689, encodeId=7a7d1e46689ea, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Mon Mar 16 04:45:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479430, encodeId=395514e9430ee, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594667, encodeId=ebd1159466ec7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602209, encodeId=a77316022090a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
    2019-11-08 yuhaisheng_ibp_32061713

    #黑素瘤#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1916186, encodeId=89fa191618662, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 12 02:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910527, encodeId=5a23191052eb0, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Wed Sep 23 12:45:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746689, encodeId=7a7d1e46689ea, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Mon Mar 16 04:45:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479430, encodeId=395514e9430ee, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594667, encodeId=ebd1159466ec7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602209, encodeId=a77316022090a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
    2019-11-08 智智灵药

    #III期#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1916186, encodeId=89fa191618662, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 12 02:45:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910527, encodeId=5a23191052eb0, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Wed Sep 23 12:45:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746689, encodeId=7a7d1e46689ea, content=<a href='/topic/show?id=fd271844257' target=_blank style='color:#2F92EE;'>#VIP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18442, encryptionId=fd271844257, topicName=VIP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=933235833639, createdName=chendoc254, createdTime=Mon Mar 16 04:45:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479430, encodeId=395514e9430ee, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594667, encodeId=ebd1159466ec7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602209, encodeId=a77316022090a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Nov 08 23:45:00 CST 2019, time=2019-11-08, status=1, ipAttribution=)]
    2019-11-08 sunylz

    #PRO#

    0